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ABSTRACT 
Background 
To investigate the cortical and white matter changes which underlie cognitive impairment in patients 
with incident Parkinson disease (PD) disease using voxel-based morphometry and diffusion tensor 
imaging (DTI). 
Methods 
Newly diagnosed non-demented PD (n=125) and control subjects (n=50) were recruited from the 
Incidence of Cognitive Impairment in Cohorts with Longitudinal Evaluation in Parkinson’s disease 
study and completed cognitive assessments and 3T structural and diffusion tensor MR imaging.  
Voxel-based morphometry was performed to investigate the relationship between gray matter 
volume and cognitive ability.  Microstructural white matter changes were assessed with DTI 
measures of fractional anisotropy (FA) and mean diffusivity (MD) using tract-based spatial statistics. 
Results 
Increased MD was seen bilaterally in subjects with PD relative to controls (P=0.019).  Increased MD 
was associated with performance on the semantic fluency and Tower of London tasks in frontal and 
parietal white matter tracts including the cingulum, superior longitudinal fasciculus, inferior 
longitudinal fasciculus, and inferior fronto-occipital fasciculus.  There was no difference in total gray 
matter volume between the groups, however, bilateral reductions in frontal and parietal gray matter 
volume were associated with reduced performance on measures of executive function in the PD 
subjects. 
Conclusions 
At the earliest stages of PD, regionally specific increases in central white matter MD are present and 
suggest early axonal damage.  Such changes are not accompanied by significant gray matter volume 
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loss and are consistent with proposed models of the pathological progression of the disease.  
Structural MRI, especially DTI analysis, offers potential as a non-invasive biomarker reflecting 
cognitive impairment in PD. 
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INTRODUCTION 
The early identification of Parkinson’s disease (PD) patients at high risk of developing Parkinson’s 
disease dementia (PDD) is of prognostic importance.  Additionally, it enables clinical trials of disease 
modifying interventions targeted at dementia to be instituted early in the disease process prior to 
extensive neuronal loss.  Mild cognitive impairments occur in 20 – 40% of patients with newly 
diagnosed PD1-4; these patients may be at highest risk of subsequently developing PDD.5  This 
process is driven by disruption of dopaminergic, cholinergic and serotonergic neurotransmitter 
systems secondary to abnormal α-synuclein aggregation; however, cortical Lewy body disease and 
the contribution of amyloid, tau and vascular pathologies can also be factors.6, 7   
Structural MRI is an established biomarker in observational and interventional studies of Alzheimer’s 
disease.  Most studies using region of interest (ROI), voxel-based morphometry (VBM) and cortical 
thickness analysis approaches have not found significant gray matter loss in patients with early, 
cognitively intact PD (PD-NC), although mild posterior atrophy was reported in one series. 8-12  Gray 
matter loss involving parietal, temporal, and occipital regions is a consistent finding in PDD.8, 11, 13-18  
More limited gray matter loss has been reported in subjects with PD-MCI.8, 11, 17, 19, 20  In a two year 
longitudinal study, PD-MCI subjects who developed dementia had lower gray matter density at 
baseline in the prefrontal cortex, insular cortex, and caudate nuclei than PD-MCI patients who did 
not subsequently convert.21 
Diffusion tensor imaging (DTI) is a sensitive technique for detecting microstructural white matter 
pathology.  Through quantifying the magnitude and directionality of the motion of water molecules 
it provides an in vivo surrogate measure of the integrity of tissue microstructure.  Degeneration of 
structural barriers such as myelin and cell membranes increases mean diffusivity (MD) and lowers 
the directionality of its flow, measured as fractional anisotropy (FA).  Tract-based spatial statistics 
(TBSS) interrogates the integrity of white matter tracts without the limits of the operator-dependent 
ROI approach.22  Changes in FA and MD have been reported in both PDD12, 23, 24  and PD-MCI.23 
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We sought evidence of alterations in regional gray matter volume and integrity of the principal white 
matter tracts in patients with newly diagnosed PD.  We hypothesized that because increased MD is a 
sensitive marker of white matter damage, changes in MD would be detectable prior to reduced FA23, 
25 and significant gray matter loss. 
METHODS 
Subjects 
All patients and controls were enrolled prospectively as part of the Incidence of Cognitive 
Impairment in Cohorts with Longitudinal Evaluation in Parkinson’s Disease (ICICLE-PD) Study.4, 26  All 
patients with newly diagnosed PD attending movement disorder, neurology, and geriatric medicine 
clinics in Newcastle and Gateshead between 1st June 2009 and 31st December 2011 were invited to 
participate.  Enrolled subjects fulfilled the UK Brain Bank Criteria for idiopathic PD.27  Healthy and 
unrelated control subjects were recruited from the local community. 
Exclusion criteria comprised: patients with parkinsonism diagnosed prior to the onset of the study; 
insufficient working knowledge of English; significant cognitive impairment or dementia at 
presentation; and the use of antipsychotic medication.  Patients were reviewed after 18 months to 
ensure that other causes of parkinsonism were excluded. 
The study was approved by the Newcastle and North Tyneside Research Ethics Committee.  All 
subjects provided written informed consent. 
Clinical and neuropsychological assessment 
Clinical, neuropsychological, and imaging assessments were completed for each participant within a 
4 month period.  Assessments included a standardized neurological examination, Hoehn and Yahr 
(H&Y) staging,28 the Movement Disorders Society-revised Unified Parkinson’s Disease Rating Scale 
(MDS-UPDRS) part III,29 and the Geriatric Depression Scale (GDS-15).30  Patients were assessed while 
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taking their normal regimen of dopaminergic and other medications.  Dopaminergic medication 
doses were standardized and are presented as levodopa equivalent daily dose (LEDD).31 
Global cognitive function was assessed with the Mini-Mental State Examination (MMSE)32 and 
Montreal Cognitive Assessment (MoCA).33   Attention was measured using tests from the Cognitive 
Drug Research (CDR) battery.  Scores of simple reaction time, choice reaction time, and digit 
vigilance were summed to produce a composite power of attention (PoA) score.34  Memory was 
assessed with the spatial recognition memory, pattern recognition memory, and paired associates 
learning subsets from the Cambridge Neuropsychological Test Automated Battery (CANTAB).35  
Executive function was measured using tests of phonemic fluency (words beginning with F, A, and S 
for 60 seconds each)36 and semantic fluency (animals named in 90 seconds)37 and with the Tower Of 
London task from the CANTAB battery.38 
MRI acquisition 
All images were acquired using a 3T Intera Achieva scanner (Philips Medical Systems, Eindhoven, 
Netherlands) with an 8-channel receiver head coil in a single session.  A standard sagittal T1-
weighted volumetric scan was acquired covering the whole brain using a magnetization prepared 
rapid gradient echo (MP-RAGE) sequence: echo time (TE) = 4.6ms; repetition time (TR) = 9.6ms; flip 
angle=8°, SENSE factor = 2.  In-plane field of view (FOV) = 240x240mm, slice thickness = 1.2mm, 
voxel size = 1.15×1.15mm.  DTI acquisitions were based on a 2-dimensional diffusion-weighted, spin-
echo, echo planar imaging sequence with 59 slices: TR=6100ms; TE=70ms; flip angle=90°; voxel size= 
2.1x2.1mm; slice thickness = 2.1mm; FOV=270x270mm.  Diffusion-weighting was performed in 64 
uniformly distributed directions (diffusion b=1000 s.mm-2) and in 6 acquisitions without diffusion 
weighting (b= 0 s.mm-2). 
MRI pre-processing 
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Images were inspected for any artefacts or gross abnormalities and were processed using Statistical 
Parametric Mapping (SPM8) (http://www.fil.ion.ucl.ac.uk/spm) and MATLAB 7.14 (Math-Works, 
Natick, MA, USA).39  T1-weighted images were segmented into gray matter, white matter, and 
cerebral spinal fluid (CSF) using the standard unified segmentation sequence in SPM8.  These images 
were also inspected for segmentation classification errors.  A study-specific gray matter template 
was created from all patients and controls using the diffeomorphic anatomical registration through 
exponentiated Lie algebra (DARTEL) toolbox in SPM8.40  Gray matter data were spatially normalized 
and warped in DARTEL and transformed to Montreal Neurological Institute (MNI) space 
(http://www.mni.mcgill.ca).  Images were Jacobian modulated to preserve the relative volumes of 
gray matter following normalization.  An 8mm full-width half maximum (FWHM) Gaussian kernel 
was used to smooth the images.  The smoothed, modulated and normalized gray matter datasets 
were used for the statistical analyses.  Total intracranial volume (TIV) was calculated by summing the 
total tissue assignments to gray matter, white matter, and CSF from probability maps generated in 
the initial segmentation step. 
DTI pre-processing 
Pre-processing was performed using TBSS in FSL (http://fsl.fmrib.ox.ac.uk/fsl/tbss).22  To correct for 
distorting effects of eddy currents a modified version of the technique described by Shen et al41 was 
used with an affine registration to register pairs of diffusion-weighted images together.  The 
diffusion-weighted images were then co-aligned with a rigid body registration to the b = 0 s.mm-2 
image.  MD and FA maps were calculated using the FSL tensor analysis of the aligned diffusion-
weighted images at each brain voxel.  First, the individual FA images from all subjects were each 
nonlinearly aligned to the pre-defined FSL FMRIB58 FA map using a resolution of 1mm in the 
standard MNI152 space.  The data were checked visually to ensure accuracy of the nonlinear 
transformation process.  A mean FA image was created and thinned to create a mean FA skeleton, 
which represented the centers of all tracts common to the group.  Finally, the aligned FA and MD 
9 
 
image for each subject was projected onto the constructed skeleton.  Voxel-wise statistical analyses 
of FA and MD data were performed using TBSS to compare group differences between the white 
matter skeletons. 
Statistical analyses 
Clinical and neuropsychological data were analyzed with Statistical Package for Social Sciences (SPSS 
version 19).  Independent t-tests were used to compare normally distributed continuous variables 
and the Mann-Whitney U test was used for continuous data without a normal distribution.  Pearson 
Chi squared tests were used to compare categorical data, except where the number in a category 
was less than five, in which case Fisher’s exact test was used.  Significant results were reported at a 
P<0.05.  Bonferroni adjustment was performed to correct for multiple testing of neuropsychological 
data, yielding a p < 0.007 level of significance.    Consistent with recent recommendations,42 and to 
make this study comparable with the work of others,43, 44 a test score was considered impaired if it 
was 1.5 standard deviations (SD) below the mean score of the control subjects. 
Gray matter volume differences were assessed using one way ANOVAs in the SPM8 General Linear 
Model based on random Gaussian field theory.  An absolute threshold mask of 0.1 was used in all 
gray matter analyses.  Age, TIV, and education were included as covariates in all multiple regression 
analyses.  MDS-UPDRS part III score was included as a covariate for the PD subjects.  The relationship 
between gray matter volumes and cognitive test performance was examined.  Mean regional grey 
matter volume differences between groups (Control vs. PD-NC, PD-NC vs. PD-impaired-test, Control vs. 
PD-impaired–test) were compared by ANCOVA in SPM8, impaired being defined as test performance 
below 1.5 SD the normative mean.  Reverse contrasts were performed for all analyses.  Significant 
clusters were identified using a voxel-wise uncorrected threshold of p<0.001.  Clusters were 
regarded as significant if their extent exceeded 100 voxels.  To control for multiple comparisons a 
family-wise error (FWE) threshold of pFWE-corr<0.05 was applied.  The anatomical location was 
determined using the Talairach daemon (http://talairach.org/). 
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Differences in MD and FA were compared between groups (Control vs. PD-NC, PD-NC vs. PD-impaired-
test, Control vs. PD-impaired–test) with a permutation-based, non-parametric test, 2-sample, unpaired t-
test in the FSL “randomize” program.  Age and education were included as covariates.  Separate FA 
and MD models excluding the controls assessed the PD subjects (PD-NC and PD-impaired-test) with the 
same covariates plus MDS-UPDRS III score.  For each contrast, 5000 permutations of the data were 
generated producing statistical maps uncorrected and FWE-corrected for multiple comparisons.  
Statistical maps were interrogated using a corrected threshold of P<0.05.  The threshold-free cluster 
enhancement (TFCE) algorithm was used to identify significant clusters and control for multiple 
comparisons.45  Regions showing significant differences between groups were located and labelled 
by mapping the statistical map to the John Hopkins University DTI white matter atlas within FSL. 
RESULTS 
Participant characteristics 
Table 1 shows that subject groups were similar in age, gender, and education.  Although those with 
PD reported more depressive symptoms on the GDS-15 compared with controls, there was no 
difference in the prevalence of clinically diagnosed depression.  Nor were there significant 
differences in the prevalence of cardiovascular disease risk factors. 
Table 1.  Demographic and clinical characteristics of the Parkinson’s disease and control subjects. 
The results of the cognitive testing are shown in Table 2.  After Bonferroni correction for multiple 
testing, subjects with PD had small, but significant, reductions in performance on tests of global 
cognition and all domain specific cognitive tests compared with controls. 
Table 2.  Cognitive test data of the Parkinson’s disease and control subjects. 
Voxel-based morphometry 
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There was no significant difference in total or regional gray matter volumes between the entire PD 
group and the control subjects (P=0.58), nor following correction for total intracranial volume 
(P=0.42).  Reduced gray matter volume in frontal, parietal, and temporal areas in the PD subjects 
was associated with poorer performance on the semantic fluency task (PFWE-corr<0.05) (Table 3 and 
Figure 1a).  Reduced gray matter volume in frontal and parietal areas was evident in PD subjects 
with impaired semantic fluency (PD-impaired-SF), when compared with PD subjects with normal fluency 
performance and the control subjects.  A relationship between reduced gray matter volumes in 
frontal and parietal areas and poor performance on the executive Tower of London task was also 
observed in PD subjects (Figure 1b).  However, no mean differences were seen between groups 
(Control vs. PD-NC, PD-NC vs. PD-impaired-ToL or Control vs. PD-impaired-ToL).  There was no significant 
association between gray matter volume and performance on any of the other cognitive tests. 
Figure 1.  Anatomical location of clusters of reduced grey matter volume associated with cognitive 
task performance. 
Table 3.  Anatomical location of clusters of reduced gray matter volume associated with cognitive 
task performance. 
Diffusion tensor imaging 
Averaged across the entire white matter, PD subjects had greater MD than controls (0.758 x 10-
3mm2/s, range 0.717 – 0.957 vs. 0.752 x 10-3mm2/s, range 0.701 – 0.893, P=0.019).  Interrogation 
with TBSS showed MD increases bilaterally in frontal and parietal subcortical tracts including the 
forceps minor, cingulum, superior longitudinal fasciculus, inferior longitudinal fasciculus, inferior 
fronto-occipital fasciculus, corticospinal tract, corpus callosum, and internal capsule (Figure 2A and 
2B).  These changes were also observed in PD subjects with impaired semantic fluency (PD-impaired-SF) 
relative to PD-NC and controls (Figure 2C).  There were no areas where the controls had higher MD 
values than the subjects with PD.  There was no difference in total FA between the control and PD 
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subject groups (0.42, range 0.37 – 0.48 vs. 0.42, range 0.32 – 0.48, P=0.255), nor was there any 
significant association between FA and cognitive test performance. 
Figure 2.  Associations between MD and performance on the semantic fluency and Tower of London 
tasks.  
DISCUSSION 
In this large series of patients with newly diagnosed PD we found that altered MRI measures of 
white matter integrity and gray matter volume correlated with cognitive decline.  The principal 
findings were: (1) Increases in the MD of central white matter tracts were detectable in the absence 
of reductions in either FA or gray matter volume; (2) Increased MD in frontal and parietal tracts and 
reduced gray matter volume in frontal, parietal, and temporal areas correlated with poor 
performance on the semantic fluency and executive Tower of London tasks. 
These findings in our cohort of patients with newly diagnosed PD, extend the work of Melzer et al 23 
who observed increased MD in the absence of significant reductions in FA in patients with 
established PD targeting frontal and parietal tracts with involvement of the external capsule, 
corticospinal tract, corpus callosum, inferior occipital fasciculus, and inferior longitudinal fasciculus.  
Together, these results indicate that degeneration of central white matter tracts occurs early in PD 
and may underlie early cognitive dysfunction.  Widespread increases in MD involving the major 
white matter tracts have been reported in PDD.23  TBSS has detected reductions in FA in the superior 
longitudinal fasciculus, inferior longitudinal fasciculus, inferior fronto-occipital fasciculus, uncinate 
fasciculus, and cingulum in PDD relative to age-matched controls.12  In the same study, patients with 
PDD had lower FA values in the superior longitudinal fasciculus, inferior longitudinal fasciculus, 
inferior fronto-occipital fasciculus, uncinate fasciculus, cingulum, and corpus callosum compared 
with PD-NC subjects.  However, these changes were not present in PD-NC subjects, supporting our 
findings and suggesting that decreases in FA appear later than rises in MD during the disease.  
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Increases in MD may occur with minimal or even absent alterations in FA and have been observed in 
studies of both AD and PD.23, 25  Although the pathological substrate underlying DTI changes is  
unclear, such changes may result from similar proportional variations in the measured tensor 
dimensions within the diffusion ellipsoid caused by the neurodegenerative process25 and not solely 
changes in the longitudinal diffusivities.  The pathogenesis of white matter damage in PD is not well 
understood.  Lewy neurites are the axonal manifestation of α-synuclein pathology and may be 
associated with impaired axonal transport with subsequent microstructural changes in the axon or 
surrounding myelin.  Indeed, there is now evidence to suggest that PD is primarily a result of 
synaptic dysfunction with early axonal transport problems leading to subsequent cell death.46 
Our finding of normal cortical volumes in newly diagnosed PD-NC patients is in line with other VBM 
studies of early PD 10, 11 and Braak neuropathological staging of the disease. 47 We are aware of only 
one other study of PD-NC patients, and this reported a small cluster of gray matter loss in the 
occipital lobe relative to controls.8  In PD-MCI, gray matter loss is evident in temporal, parietal, and 
frontal regions.11, 19, 21  Subsequently, with disease progression and the onset of dementia, diffuse 
gray matter loss becomes evident.11, 13 
The association of raised MD and reduced frontal gray matter volume changes with impaired 
semantic fluency in early PD is a novel finding.  In established PD, gray matter density changes in the 
inferior and middle frontal gyrus and in the temporal lobe have been reported to correlate with 
semantic fluency performance.48  Semantic fluency is more than a measure of executive function and 
is closely related to temporal lobe function.  In PD it is reported to be more significantly impaired 
relative to phonemic fluency.49  This may indicate that the cognitive speed and retrieval of semantic 
items may represent an additional dysfunction of semantic memory.49  Longitudinal studies of 
cognition in PD report that impaired semantic fluency may herald the development, or be an early 
feature, of PDD.50, 51 
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The involvement of the cingulate gyrus and its white matter connections to the thalamus and 
entorhinal cortex via the cingulum in PD is noteworthy.  The cingulate is critical to the regulation of 
mood and autonomic function; moreover, it plays a key role in working and planning memory, 
attention and visuospatial skills, all of which may be impaired in early PD.  It is reported to be 
particularly vulnerable to Lewy pathology and may be one of the earliest sites of limbic involvement 
in PD MRI studies report cingulate grey matter loss in PDD and changes in this structure detectable 
with MRI may prove a useful marker of early disease progression.11, 15 
Strengths of our study include a large and well characterized incident cohort of patients with early 
PD.  All subjects were imaged using the same 3T scanner.  The inclusion of a control group, well 
matched for age, gender, and level of education permitted the generation of appropriate normative 
cognitive reference data.  We employed validated clinical and cognitive assessments which have 
previously been adopted by observational and interventional studies of PD and cognition.  Because 
the prognostic implications and neuroanatomical mechanisms of cognitive decline in PD are poorly 
described we avoided a generic “PD-MCI” classification and examined performance on each 
cognitive test separately.  In doing so we hoped to gain a better appreciation of the neuroanatomical 
correlates and temporal progression of changes associated with cognitive decline in PD. 
Our large cohort permitted the generation of study specific templates/skeletons for the imaging 
analyses, without reliance upon the standard templates included within analysis software packages 
which are generated from younger subjects.  The advantage of using TBSS for analyzing diffusion 
data is that it combines the ability to interrogate all white matter without the limitations of an a 
priori ROI approach.  Through enhanced alignment of the central white matter during the 
registration and skeletonisation steps, the use of non-parametric statistics and the specific TFCE 
method, TBSS has been shown to be more sensitive than voxel-based approaches.  However TBSS is 
biased towards the central white matter tracts and less sensitive to changes in peripheral white 
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matter tracts, therefore we may have been able to detect fewer MD and FA changes in these 
regions.52 
Our adoption of the UK Brain Bank criteria and use of a longitudinal study design should have 
minimized possible misdiagnoses.26, 27  Only a small proportion of patients were drug naïve, however, 
as reflects current clinical practice, MDS guidance, and other published work.8, 11, 21, 23, 42 
By performing analysis of cortical gray matter volumes and measuring the integrity of the underlying 
white matter, we have shown that MRI has the potential to become a biomarker that is associated 
with cognitive function in PD.  Our results suggest increased diffusivity is detectable before changes 
in gray matter volume.  Future work will be aimed at establishing the temporal nature of gray and 
white matter abnormalities in PD and how these and the baseline changes correlate with 
subsequent cognitive decline. 
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Figures 
Figure 1.  Anatomical location of clusters of reduced gray matter volume associated with cognitive 
task performance. 
Figure 1.  Three-dimensional surface renders showing clusters of cortical gray matter loss (red) in 
those with PD: (a) significant association between poorer performance on the semantic fluency task 
with gray matter loss in the insular cortex, precentral gyrus, and middle frontal gyrus in the right 
hemisphere, and the insular cortex and cingulate gyrus in the left hemisphere; (b) in PD impaired on 
the semantic fluency task relative to controls showing gray matter loss in the right inferior parietal 
lobule and left transverse temporal gyrus; (c) in PD impaired on the semantic fluency task compared 
with PD not impaired showing gray matter loss in the right inferior parietal lobule, left insular cortex, 
and left cingulate gyrus; and (d) association with performance on Tower of London task with areas of 
reduced gray matter in the right and left insular cortex and the right cingulate gyrus.  All results are 
presented at a cluster-wise threshold corrected PFWE-corr < 0.05.
 
Figure 2.  Associations between MD and performance on the semantic fluency and Tower of London 
tasks.  
Figure 2.  Tract-based spatial statistics map showing areas of increased MD (yellow – red) in the 
white matter in PD overlaid on the study specific mean FA skeleton (green) (A) significant association 
between increased MD and lower semantic fluency score (B) significant association between 
increased MD and poorer performance on the executive Tower of London task; and (C) in PD 
impaired on the semantic fluency task compared with PD not impaired.  All results are P<0.05, 
corrected for multiple comparisons using TFCE. 
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Tables 
Table 1. Demographic and clinical characteristics of the Parkinson’s disease and control subjects.
Values are mean ± SD, except median (range) for disease duration, education, Hoehn and Yahr stage, 
GDS, and number (%) for vascular risk factors. 
Comparisons between groups performed using a Student’s t-test, b Chi-square, c Mann-Whitney U 
test, or d Fisher’s exact test. 
Abbreviations: GDS = Geriatric Depression Scale; MDS-UPDRS-III = Movement Disorders Society 
revised Unified Parkinson’s Disease Rating scale part III
 
Table 2.  Cognitive test data of the Parkinson’s disease and control subjects. 
Values are median (range) for MMSE, MoCA, Tower of London, spatial recognition memory, pattern 
recognition memory, and paired associates learning, except for PoA, semantic, and phonemic 
fluency which are mean ± SD. 
Comparisons between groups performed using a Mann-Whitney U, b Student’s t-test or c Fisher’s 
exact test. 
Abbreviations: SD = standard deviation; MMSE = Mini-Mental State Examination; GDS = Geriatric 
Depression Scale; MoCA = Montreal Cognitive Assessment.
 
Table 3.  Anatomical location of clusters of reduced gray matter volume associated with cognitive 
task performance. 
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Location and peak significance of significant reduction in gray matter volume: (a) in patients with PD 
where gray matter volume was associated with performance on the semantic fluency task; (b) in the 
controls and those PD subjects impaired on the semantic fluency task; (c) in PD subjects with normal 
performance against those with impaired performance; (d) in PD patients where gray matter volume 
was associated with performance on the executive Tower of London task.  For each peak the table 
shows cluster-level significance (pFWE-Corr), spatial extent (k), t and z scores, MNI co-ordinates, and 
anatomical region. 
Abbreviations: L = left; MNI = Montreal Neurological Institute; PD = Parkinson’s disease; R = right. 
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GLOSSARY 
CANTAB = Cambridge Automated Neuropsychological Test Assessment Battery; CDR = Cognitive 
Drug Research; CSF = cerebrospinal fluid; DARTEL = diffeomorphic anatomical registration through 
exponentiated Lie algebra; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders fourth 
edition; DTI = diffusion tensor imaging; FA = fractional anisotropy; FSL = Functional MRI of the Brain 
Software Library package; FWE = family-wise error; FWHM = full-width half maximum; GDS-15 = 
Geriatric Depression Scale; H&Y = Hoehn and Yahr stage; ICICLE-PD = Incidence of Cognitive 
Impairment in Cohorts with Longitudinal Evaluation in Parkinson’s Disease Study; LEDD = levodopa 
equivalent daily dose; MCI = mild cognitive impairment; MD = mean diffusivity; MDS-UPDRS-III = 
Movement Disorders Society revised Unified Parkinson’s Disease Rating Scale Part III; MoCA = 
Montreal Cognitive Assessment; MMSE = Mini-Mental State Examination; PAL = Paired Associates 
Learning; PD-MCI = Parkinson’s disease with mild cognitive impairment; PoA = Power of Attention; 
PRM = Pattern Recognition Memory; ROI = region of interest analysis; SF = semantic fluency; SPM = 
Statistical Parametric Mapping; SRM = Spatial recognition memory; TBSS = tract-based spatial 
statistics; TE = echo time; TFCE = threshold-free cluster enhancement; TI = inversion time; TIV = total 
intracranial volume; ToL = Tower of London task; TR = repetition time; VBM = voxel-based 
morphometry. 
 
Table 1.  Demographic and clinical characteristics of the Parkinson’s disease and control subjects. 
 Control (n = 50) PD (n = 125) P Value 
Demographics 
Age, y 65.8 ± 8.0 66.0 ± 10.5 0.88a 
Gender, male (% male) 29 (58) 85 (68) 0.21b 
Education, y 11.5 (3 - 24) 12 (3 – 24) 0.36c 
Clinical information 
Disease duration, months - 6.15 (4.66) - 
MDS-UPDRS III - 26.8 ± 11.1 - 
Hoehn and Yahr Stage - 2 (1 - 3) - 
Levodopa equivalent dose, mg/d - 175 (0 - 590) - 
GDS-15 (0 - 15) 0 (0 - 7) 2 (0 - 12) <0.001c 
Vascular risk factors, n (%) 
Diabetes 1 (2) 10 (8) 0.18d 
Ischaemic heart disease 3 (6) 13 (10.4) 0.56d 
Hypertension 13 (26) 38 (30.4) 0.56b 
Hypercholesterolaemia 10 (20) 16 (12.8) 0.23b 
Transient ischaemic attack 0 (0) 10 (8) 0.06d 
Ever smoked 27 (54) 55 (44) 0.26b 
 
Values are mean ± SD, except median (range) for disease duration, education, Hoehn and Yahr stage, 
GDS, and number (%) of vascular risk factors. 
Comparisons between groups performed using a Student’s t-test, b Chi-square, c Mann-Whitney U 
test, or d Fisher’s exact test. 
Abbreviations: GDS = Geriatric Depression Scale; MDS-UPDRS-III = Movement Disorders Society 
revised Unified Parkinson’s Disease Rating scale part III 
Table 2.  Cognitive test data of the Parkinson’s disease and control subjects. 
 Control (n = 50) PD (n = 125) P Value* 
Global Cognitive testing 
MMSE (0 - 30) 30 (26 - 30) 29 (24 - 30) 0.003a 
MoCA (0 – 30) 28 (21 - 30) 26 (16 - 30) <0.001a 
Cognitive tests  
Power of attention, ms  1242 ± 116 1363 ± 198 <0.001b 
Impaired at 1.5 SD, n (%) 2 (4) 28 (22.6) 0.003c 
Semantic fluency (words) 24.4 ± 6.3 21.2 ± 6.8 0.004b 
Impaired at 1.5 SD, n (%) 4 (8.0) 19 (15.2) 0.22c 
Phonemic fluency (words) 41.6 ± 12.9 33.0 ± 12.4 <0.001b 
Impaired at 1.5 SD, n (%) 3 (6) 20 (16) 0.13c 
Tower of London (0 – 20) 17 (9 - 20) 15 (1 - 20) <0.001a 
Impaired at 1.5 SD, n (%) 3 (6.0) 25 (20.0) 0.07c 
Spatial recognition memory (0 – 20) 17 (3 - 20) 16 (9 - 20) <0.001a 
Impaired at 1.5 SD, n (%) 1 (2) 29 (23.2) 0.004c 
Pattern recognition memory (0 – 24) 22 (15 - 24) 20 (11 - 24) 0.001a 
Impaired at 1.5 SD, n (%) 2 (4) 25 (20.0) 0.030c 
Paired associates learning 1.63 (1.13 -3.57) 1.88 (1 - 7) 0.002b 
Impaired at 1.5 SD, n (%) 3 (6) 17 (13.6) 0.35c 
 
Values are median (range) for MMSE, MoCA, Tower of London, spatial recognition memory, pattern 
recognition memory, and paired associates learning, except for PoA, semantic, and phonemic 
fluency which are mean ± SD. 
Comparisons between groups performed using a Mann-Whitney U, b Student’s t-test or c Fisher’s 
exact test. 
* Following Bonferroni correction for multiple neuropsychological tests, p < 0.007 was considered a 
significant difference in test scores between subjects with PD and controls. 
 
Abbreviations: SD = standard deviation; MMSE = Mini-Mental State Examination; GDS = Geriatric 
Depression Scale; MoCA = Montreal Cognitive Assessment. 
Table 3.  Anatomical location of clusters of reduced gray matter volume associated with cognitive 
task performance. 
Brain Region Cluster-
Wise value 
(pFWE-corr)  
Cluster 
size (k) 
Peak 
voxel 
T, Z 
MNI Co-ordinates (mm) 
X Y Z 
(a) Association between gray matter volume and semantic fluency scores 
R insular cortex 0.001 3092 5.73, 
5.37 
45 -12 10 
R precentral gyrus 0.002 1697 5.26, 
4.97 
59 12 10 
R middle frontal gyrus 0.037 871 4.60, 
4.40 
30 59 1 
L insular cortex 0.003 1605 5.07, 
4.81 
-48 -18 16 
L cingulate gyrus 0.002 1792 4.23, 
4.07 
-3 -9 45 
(b) Controls > PD-impaired-semantic fluency 
R inferior parietal lobule 0.040 888 4.66, 
4.31 
63 -19 27 
L transverse temporal 
gyrus 
0.013 1217 4.47, 
4.16 
-51 -21 12 
(c) PD-NC > PD-impaired-semantic fluency 
R inferior parietal lobule 0.001 2189 4.57 64 -19 27 
L insular cortex 0.028 1006 4.17, 
4.01 
-42 -18 12 
L cingulate gyrus 0.035 947 4.13, 
3.98 
-4 -10 45 
(d) Association between gray matter volume and performance on Tower of London task 
R insular cortex 0.002 1848 5.61, 
5.26 
41 21 -0 
R insular cortex 0.020 1070 4.55, 
4.35 
39 -12 15 
R cingulate gyrus 0.031 956 4.38, 
4.20 
9 -30 45 
L insular cortex 0.005 1524 5.08, 
4.81 
-39 17 3 
 
Location and peak significance of significant reduction in gray matter volume: (a) in patients with PD 
where gray matter volume was associated with performance on the semantic fluency task; (b) in the 
controls and those PD subjects impaired on the semantic fluency task; (c) in PD subjects with normal 
performance against those with impaired performance; (d) in PD patients where gray matter volume 
was associated with performance on the executive Tower of London task.  For each peak the table 
shows cluster-level significance (pFWE-Corr), spatial extent (k), t and z scores, MNI co-ordinates, and 
anatomical region. 
Abbreviations: L = left; MNI = Montreal Neurological Institute; PD = Parkinson’s disease; R = right. 
 

  
